DEANER AN ADJUNCT FOR TREATMENT OF SCHIZOID AND SCHIZOPHRENIC PATIENTS
Abstract
Despite the small number of patients included in this study, certain clinical impressions were formed: Deaner appears to merit further study in those conditions where CNS stimulation is needed. Its freedom from serious side-effects, and the dramatic response produced in some cases suggest that the drug is worthy of trial, especially in schizoid and schizophrenic patients who have not responded to other therapies.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
